In this large population study co-authored by Therapeutics Initiative researcher Dr. Colin Dormuth, “the use of incretin based drugs was not associated with an increased risk of pancreatic cancer compared with sulfonylureas. Although this potential adverse drug reaction will need to be monitored long term owing to the latency of the cancer, these findings provide some reassurance on the safety of incretin based drugs.”
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay Laurent, Filion Kristian B, Platt Robert W, Dahl Matthew, Dormuth Colin R, Clemens Kristin K et al.
BMJ 2016; 352 doi: http://dx.doi.org/10.1136/bmj.i581 (Published 17 February 2016)